GYRE — Gyre Therapeutics Inc.

Gyre Therapeutics Inc. (GYRE) is a biotechnology company listed on NASDAQ. It is led by Ying Luo Ph.D., based in 12730 High Bluff Drive, San Diego, CA, United States, 92130, with about 625 employees. Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Latest reported GYRE revenue for 2025-09-30 was $30.6M. Net income was $11.2M. Revenue was up 14.2% from 2025-06-30 to 2025-09-30. GYRE currently screens at market cap $589.9M.

Use this GYRE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GYRE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GYRE SEC filings page. Lician reads the product cache first so this HTML stays unique to Gyre Therapeutics Inc. even when a live quote feed is slow.